PT  - JOURNAL ARTICLE
AU  - Trauer, James M
AU  - Hughes, Angus E
AU  - Shipman, David S
AU  - Meehan, Michael T
AU  - Henderson, Alec S
AU  - McBryde, Emma S
AU  - Ragonnet, Romain
TI  - A Data Science Pipeline Applied to Australia’s 2022 COVID-19 Omicron Waves
AID  - 10.1101/2023.12.04.23299260
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.12.04.23299260
4099  - http://medrxiv.org/content/early/2023/12/05/2023.12.04.23299260.short
4100  - http://medrxiv.org/content/early/2023/12/05/2023.12.04.23299260.full
AB  - The field of software engineering is advancing at astonishing speed, with packages now available to support many stages of data science pipelines. These packages can support infectious disease modelling to be more robust, efficient and transparent, which has been particularly important during the COVID-19 pandemic. We developed a package for the construction of infectious disease models, integrated this with several open-source libraries and applied this pipeline to multiple data sources that provided insights into Australia’s 2022 COVID-19 epidemic. We aimed to identify the key processes relevant to COVID-19 transmission dynamics and thereby develop a model that could quantify relevant epidemiological parameters. Extending the base model to include mobility effects slightly improved model fit to data, but including the effect of 2022 vaccination programs on transmission did not. Our simulations suggested that one in every two to six COVID-19 episodes were detected, subsequently emerging Omicron subvariants escaped 30 to 60% of recently acquired natural immunity and that natural immunity lasted only one to eight months. We documented our analyses algorithmically and present our methods in conjunction with interactive online notebooks.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJames Trauer is supported by a Discovery Early Career Researcher Award from the Australian Research Council (DE230100730). The Epidemiological Modelling Unit at the School of Public Health and Preventive Medicine (EMU) was supported by a Rapid Research Digital Infrastructure COVID-19 grant from the Medical Research Future Fund during 2021 and 2022. EMU also provided modelling to countries of the Asia-Pacific through a series of contracts with the World Health Organization Western Pacific and South East Asia Regional Offices over the course of the pandemic, through which much of the software development underpinning this analysis was undertaken.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study only used publicly accessible human data from various data sources. These were originally available from: https://www.health.gov.au/health-alerts/covid-19/weekly-reporting, https://github.com/owid/covid-19-data/tree/master/public/data#license, https://www.health.gov.au/our-work/nndss, https://covid19.who.int/WHO-COVID-19-global-data.csv, https://www.kirby.unsw.edu.au/sites/default/files/documents/COVID19-Blood-Donor-Report-Round4-Nov-Dec-2022_supplementary%5B1%5D.pdf, https://ec.europa.eu/eurostat, https://www.google.com/covid19/mobility/ and the Australian Bureau of Statistics website.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesEvery aspect of this analysis from input data, through methodological techniques, to model output estimates are publicly available through our GitHub repository. https://github.com/monash-emu/aust-covid https://monash-emu.github.io/outputs/aust-covid/